Literature DB >> 33061193

Strategies for tricuspid valve repair.

Nishant Saran1, Joseph A Dearani1.   

Abstract

Tricuspid valve repair is in many ways more challenging than mitral valve repair, especially since tricuspid valve anatomy is more complex with three leaflets, a saddle-shaped dynamic annulus and a complex subvalvular apparatus. The late referral of patients for tricuspid valve surgery adds to this challenge and contributes to poor prognosis. Nevertheless, studies have shown that the presence of moderate or greater tricuspid valve regurgitation leads to poor survival. Consequently, tricuspid valve surgery is now being performed more often, in order to improve the quality of life and survival. Tricuspid valve disease can be broadly classified into congenital and acquired tricuspid valve pathologies. Various repair techniques besides simple annular reduction maneuvers are used which are primarily aimed at restoring the complex interplay of various anatomical components. This review is a summary of the various operative techniques which provide successful reproducible results and achieve a competent and durable tricuspid valve repair with satisfactory late outcomes. © Indian Association of Cardiovascular-Thoracic Surgeons 2019.

Entities:  

Keywords:  Cone repair; Tricuspid valve; Tricuspid valve repair

Year:  2019        PMID: 33061193      PMCID: PMC7525728          DOI: 10.1007/s12055-019-00826-x

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  17 in total

1.  Midterm outcomes of tricuspid valve repair versus replacement for organic tricuspid disease.

Authors:  Steve K Singh; Gilbert H L Tang; Manjula D Maganti; Susan Armstrong; William G Williams; Tirone E David; Michael A Borger
Journal:  Ann Thorac Surg       Date:  2006-11       Impact factor: 4.330

2.  Outcomes of tricuspid valve repair and replacement: a propensity analysis.

Authors:  Robert J Moraca; Marc R Moon; Jennifer S Lawton; Tracey J Guthrie; Kristen A Aubuchon; Nader Moazami; Michael K Pasque; Ralph J Damiano
Journal:  Ann Thorac Surg       Date:  2009-01       Impact factor: 4.330

3.  Outcome of tricuspid valve surgery in the presence of permanent pacemaker.

Authors:  Nishant Saran; Sameh M Said; Hartzell V Schaff; Simon Maltais; John M Stulak; Kevin L Greason; Richard C Daly; Alberto Pochettino; Katherine S King; Joseph A Dearani
Journal:  J Thorac Cardiovasc Surg       Date:  2017-12-19       Impact factor: 5.209

4.  Surgical management of congenital (non-Ebstein) tricuspid valve regurgitation.

Authors:  Sameh M Said; Harold M Burkhart; Joseph A Dearani
Journal:  Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu       Date:  2012

Review 5.  Evidence-based surgical management of acquired tricuspid valve disease.

Authors:  Sung Ho Shinn; Hartzell V Schaff
Journal:  Nat Rev Cardiol       Date:  2013-02-12       Impact factor: 32.419

6.  Improving Results of Surgery for Ebstein Anomaly: Where Are We After 235 Cone Repairs?

Authors:  Kimberly A Holst; Joseph A Dearani; Sameh Said; Roxann B Pike; Heidi M Connolly; Bryan C Cannon; Kristen L Sessions; Megan M O'Byrne; Patrick W O'Leary
Journal:  Ann Thorac Surg       Date:  2017-11-24       Impact factor: 4.330

7.  Tricuspid Valve Repair: How I Teach It.

Authors:  Nishant Saran; Joseph A Dearani
Journal:  Ann Thorac Surg       Date:  2018-03       Impact factor: 4.330

8.  The risk and outcomes of reoperative tricuspid valve surgery.

Authors:  Reubendra Jeganathan; Susan Armstrong; Bassel Al-Alao; Tirone David
Journal:  Ann Thorac Surg       Date:  2012-10-25       Impact factor: 4.330

9.  Management of tricuspid regurgitation in congenital heart disease: is survival better with valve repair?

Authors:  Sameh M Said; Joseph A Dearani; Harold M Burkhart; Heidi M Connolly; Ben Eidem; Paul E Stensrud; Hartzell V Schaff
Journal:  J Thorac Cardiovasc Surg       Date:  2013-09-29       Impact factor: 5.209

Review 10.  Secondary tricuspid valve regurgitation: a forgotten entity.

Authors:  Pilar Tornos Mas; José F Rodríguez-Palomares; Manuel J Antunes
Journal:  Heart       Date:  2015-11       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.